Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?

Nature Clinical Practice Rheumatology volume 2, pages 242–243 (2006)Cite this article

boxed-textBreedveld FC et al. (2006) The PREMIER study: a multicenter, randomized, double-blind, clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26–37

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Maini RN et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563

    Article  CAS  Google Scholar 

  2. St Clair EW et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 50: 3432–3443

    Article  CAS  Google Scholar 

  3. Lipsky, PE et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602

    Article  CAS  Google Scholar 

  4. Klareskog L et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681

    Article  CAS  Google Scholar 

  5. Smolen JS et al. (2005) Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT trial. Arthritis Rheum 52: 1020–1030

    Article  CAS  Google Scholar 

  6. Smolen JS and Aletaha D (2004) Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 63: 221–225

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and the Chairman of the Division of Rheumatology,

    Josef S Smolen

  2. Fellow in Rheumatology, at the Medical University of Vienna, Vienna, Austria

    Daniel Aletaha

Authors
  1. Josef S Smolen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Aletaha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josef S Smolen.

Ethics declarations

Competing interests

JS Smolen is an advisory board member for several companies, including Abbott, Centocor, Schering-Plough and Wyeth. He was also principal investigator on the ASPIRE trial.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smolen, J., Aletaha, D. Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?. Nat Rev Rheumatol 2, 242–243 (2006). https://doi.org/10.1038/ncprheum0171

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0171

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing